MA27087A1 - Compositions pharmaceutiques comprenant le glibenclamide et la metformine destinees au traitement du diabete sucre de type ii - Google Patents

Compositions pharmaceutiques comprenant le glibenclamide et la metformine destinees au traitement du diabete sucre de type ii

Info

Publication number
MA27087A1
MA27087A1 MA27696A MA27696A MA27087A1 MA 27087 A1 MA27087 A1 MA 27087A1 MA 27696 A MA27696 A MA 27696A MA 27696 A MA27696 A MA 27696A MA 27087 A1 MA27087 A1 MA 27087A1
Authority
MA
Morocco
Prior art keywords
glibenclamide
metformin
diabetes
treatment
pharmaceutical compositions
Prior art date
Application number
MA27696A
Other languages
English (en)
Inventor
Alessandro Tosetti
Mauro Guiducci
Giovanni Viti
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11442301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27087(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of MA27087A1 publication Critical patent/MA27087A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA27696A 2001-11-29 2004-05-24 Compositions pharmaceutiques comprenant le glibenclamide et la metformine destinees au traitement du diabete sucre de type ii MA27087A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001FI000230A ITFI20010230A1 (it) 2001-11-29 2001-11-29 Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii

Publications (1)

Publication Number Publication Date
MA27087A1 true MA27087A1 (fr) 2004-12-20

Family

ID=11442301

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27696A MA27087A1 (fr) 2001-11-29 2004-05-24 Compositions pharmaceutiques comprenant le glibenclamide et la metformine destinees au traitement du diabete sucre de type ii

Country Status (39)

Country Link
US (1) US20050053661A1 (fr)
EP (1) EP1458364B1 (fr)
JP (1) JP4474162B2 (fr)
KR (1) KR20040079898A (fr)
CN (1) CN1596103B (fr)
AR (1) AR037407A1 (fr)
AT (1) ATE387190T1 (fr)
AU (1) AU2002358061B2 (fr)
BR (1) BR0214403A (fr)
CA (1) CA2466677A1 (fr)
CO (1) CO5590906A2 (fr)
CY (1) CY1107966T1 (fr)
DE (1) DE60225331T2 (fr)
DK (1) DK1458364T3 (fr)
EA (1) EA006766B1 (fr)
EG (1) EG24124A (fr)
ES (1) ES2302862T3 (fr)
HN (1) HN2002000341A (fr)
HR (1) HRP20040501A2 (fr)
HU (1) HUP0402154A3 (fr)
IL (1) IL162143A0 (fr)
IT (1) ITFI20010230A1 (fr)
MA (1) MA27087A1 (fr)
MX (1) MXPA04004974A (fr)
MY (1) MY141243A (fr)
NO (1) NO20042713L (fr)
NZ (1) NZ533779A (fr)
PA (1) PA8559801A1 (fr)
PE (1) PE20030580A1 (fr)
PL (1) PL206016B1 (fr)
PT (1) PT1458364E (fr)
RS (1) RS50937B (fr)
SI (1) SI1458364T1 (fr)
SV (1) SV2004001415A (fr)
TN (1) TNSN04095A1 (fr)
UA (1) UA81615C2 (fr)
UY (1) UY27549A1 (fr)
WO (1) WO2003045355A1 (fr)
ZA (1) ZA200404880B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434169C (fr) * 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Systeme de liberation espacee de medicaments
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
UY29445A1 (es) * 2005-03-30 2006-10-02 Generex Pharm Inc Composiciones para la transmisión transmucosa oral de la metformina
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI609702B (zh) * 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
CA2638240C (fr) 2008-08-29 2010-02-02 Alexander Macgregor Methode de traitement des anomalies de la glycemie et des variations de la glycemie
RU2398572C1 (ru) * 2009-05-18 2010-09-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных сахарным диабетом 2 типа
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
RU2483717C2 (ru) * 2010-11-22 2013-06-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения диабета (варианты)
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
EP2661266B1 (fr) 2011-01-07 2020-09-16 Anji Pharma (US) LLC Traitements à base de ligand de récepteur chimiosensoriel
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
EP2800562A2 (fr) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions et procédés de traitement de troubles métaboliques
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
JP6075818B2 (ja) 2014-11-11 2017-02-08 塩野義製薬株式会社 光に対して不安定な薬物を含有する多層錠剤
KR101750690B1 (ko) * 2015-10-28 2017-06-27 주식회사 종근당 메트포르민 및 로베글리타존을 포함하는 약제학적 조성물
CN105596339A (zh) * 2015-12-23 2016-05-25 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方组合物及制备方法
AU2019278015B2 (en) 2018-05-31 2024-10-03 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof
CN110128305A (zh) * 2019-05-10 2019-08-16 天津大学 二甲双胍-甲苯磺丁脲新盐型、其制备方法及医药用途
JP2021120357A (ja) * 2020-01-30 2021-08-19 サンノーバ株式会社 錠剤
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2347531A1 (de) * 1973-09-21 1975-04-30 Hoechst Ag Arzneizubereitungen zur oralen diabetes-behandlung
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
ES2206868T3 (es) * 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
CA2434169C (fr) * 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Systeme de liberation espacee de medicaments

Also Published As

Publication number Publication date
TNSN04095A1 (en) 2006-06-01
PL369851A1 (en) 2005-05-02
ZA200404880B (en) 2005-07-29
EA006766B1 (ru) 2006-04-28
AU2002358061A1 (en) 2003-06-10
EP1458364B1 (fr) 2008-02-27
HUP0402154A2 (hu) 2005-02-28
ES2302862T3 (es) 2008-08-01
EA200400664A1 (ru) 2004-10-28
RS47304A (sr) 2006-10-27
EP1458364A1 (fr) 2004-09-22
EG24124A (en) 2008-07-07
JP4474162B2 (ja) 2010-06-02
PT1458364E (pt) 2008-05-26
HUP0402154A3 (en) 2008-04-28
DK1458364T3 (da) 2008-06-23
ITFI20010230A1 (it) 2003-05-29
DE60225331T2 (de) 2009-02-26
AU2002358061B2 (en) 2007-01-11
UA81615C2 (ru) 2008-01-25
BR0214403A (pt) 2004-10-19
NO20042713L (no) 2004-07-16
HRP20040501A2 (en) 2004-12-31
WO2003045355A1 (fr) 2003-06-05
CN1596103A (zh) 2005-03-16
IL162143A0 (en) 2005-11-20
PA8559801A1 (es) 2003-06-30
CA2466677A1 (fr) 2003-06-05
MY141243A (en) 2010-03-31
PL206016B1 (pl) 2010-06-30
CO5590906A2 (es) 2005-12-30
MXPA04004974A (es) 2004-08-11
US20050053661A1 (en) 2005-03-10
HK1069974A1 (en) 2005-06-10
CN1596103B (zh) 2010-06-16
ATE387190T1 (de) 2008-03-15
JP2005518360A (ja) 2005-06-23
HN2002000341A (es) 2009-12-07
NZ533779A (en) 2007-02-23
KR20040079898A (ko) 2004-09-16
CY1107966T1 (el) 2013-09-04
SV2004001415A (es) 2004-05-07
UY27549A1 (es) 2003-06-30
PE20030580A1 (es) 2003-09-05
AR037407A1 (es) 2004-11-10
DE60225331D1 (de) 2008-04-10
RS50937B (sr) 2010-08-31
SI1458364T1 (sl) 2008-08-31

Similar Documents

Publication Publication Date Title
MA27087A1 (fr) Compositions pharmaceutiques comprenant le glibenclamide et la metformine destinees au traitement du diabete sucre de type ii
DE60307701D1 (de) Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen
EP1421933A4 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
EE200300295A (et) Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
BR9711098B1 (pt) compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
MA28740B1 (fr) Methodes de traitement d'infections endobronchiques
NO20035450D0 (no) Antranilsyreamider med en heteroarylsulfonyl sidekjede, fremgangsmåte for fremstilling derav, anvendelse som et legemiddel eller diagnostiske-og farmas degree ytiske preparater som inneholder nevnte forbindelser
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN96035A1 (fr) Derives de n-(3-benzofurannyl) uree
WO2001092283A3 (fr) Composes de cobalamine utilises en tant qu'agents cardio-vasculaires et agents d'imagerie
ATE242005T1 (de) P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes
JP2004517824A5 (fr)
EP2050442A4 (fr) Composition pharmaceutique destinée à la prévention et/ou au traitement d'une maladie osseuse, aliment fonctionnel ou aliment diététique contenant la composition, et préparation pharmaceutique contenant la composition en tant que principe actif
EE04493B1 (et) Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
EP1961764A4 (fr) Produit d'addition de chaine de sucres et de peptide et produit pharmaceutique comprenant ce produit en tant que principe actif
BRPI9910024B8 (pt) uso de uma mistura de alcoóis de açúcar contendo 6-o-alfa-d-glicopiranosil-d-sorbitol (1,6-gps) e 1-o-alfa-d-glicopiranosil-d-manitol (1,1-gpm) in vitro, e composição farmacêutica para consumo humano ou animal
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
MA26522A1 (fr) Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes.
BRPI0416246A (pt) usos de pelo menos uma das histonas h2a, h2b, h3 ou h4, de um vetor e de anticorpos, composição farmacêutica e agente ou kit diagnóstico
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
EP1440080A4 (fr) Methodes et compositions servant au diagnostic et au traitement de troubles de la proliferation cellulaire impliquant le 20750
BRPI0417796A (pt) preparado efervescente de uma substáncia básica de efeito medicinal